Acrivon Therapeutics, Inc. (ACRV): Shareholders' Equity
$112.52M
As of 2025-12-31
$86.67M
As of 2026-06-30
-12.9%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $112.52M | -36.4% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $176.79M | +45.9% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $121.19M | -28.9% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $170.47M | n/m | 2024-03-28, Balance as of period end |
| 2021-12-31 | -$23.81M | n/a | 2023-03-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $112.52M | -36.4% |
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $67.55M | -3.6% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $62.30M | -53.5% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $115.40M | -41.0% |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $44.22M | +220.8% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $98.88M | +84.8% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | -$17.00M | n/m |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $137.83M | +150.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $68.64M | -47.8% |
Compare ACRV, CTXR, SLN, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗